RSV Burden in Hong Kong

RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest.

NCT Number	NCT07321314
Lead Sponsor	Chinese University of Hong Kong
Conditions	RSV
Enrollment	10,000 participants
Start Date	2026-03-01
Primary Completion	2028-02-29 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-08